An observational study in Cardiac Disease and Metabolic Disease, sponsored by Johns Hopkins University. Enrolling by invitation at 1 site in Cameroon. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Johns Hopkins University · Observational
Cardiometabolic diseases (CMDs) are a major public health concern in sub-Saharan Africa, including Cameroon. Studies have shown a significant increase in the prevalence of hypertension, diabetes, and obesity in recent years. However, access to timely diagnosis and treatment remains limited, particularly in rural areas. Community-based screening programs have been shown to be effective in identifying individuals with undiagnosed CMD risk factors and promoting early intervention. By leveraging the strengths of community-based approaches, the URBACAM-D study aims to address the growing burden of CMDs in urban Cameroon.
2,135 studies on the registry are indexed under Heart Diseases; 252 are open to participants now.
This study's planned enrollment of 200 is below the median of 350 across 592 observational studies indexed under Heart Diseases.
Browse Heart Diseases studies →Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Urban Cameroon. Newbell, Douala, cameroon.
Inclusion Criteria:
Cardiometabolic disease screening
Prevalence of Cardiometabolic disease risk factors in Urban Cameroon
To determine the prevalence of undiagnosed and uncontrolled cardiometabolic disease (CMD) risk factors among urban Cameroonians.
Time frame: 1 year
Ran from Jul 2025 to primary completion in Oct 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.